@entity3371 . An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in XXXX and @entity712 .

@entity1 @entity1169 @entity4688 @entity712 @entity1289 @entity101 @entity8 @entity918 @entity1910 @entity644 @entity2514 @entity3371 @entity2631 @entity10129 @entity12833 @entity1398 @entity3159 @entity9804 @entity551 @entity2342
@entity3371 is an orally active inhibitor of @entity1289 ( @entity1289 ) and has been widely studied in the treatment of @entity1 with mild to moderate essential @entity101 , severe @entity101 not responsive to conventional diuretic/beta-adrenoceptor blocker/vasodilator regimens, and @entity1 with chronic @entity712 refractory to treatment with a diuretic and digitalis. In @entity1 with mild or moderate essential @entity101 , titrated low doses of @entity3371 used alone or in conjunction with a diuretic are similar in efficacy to usual doses of @entity918 , @entity9804 , or beta-adrenoceptor blocking drugs, as well as to the other @entity1289 inhibitors. In addition, @entity3371 improved well-being to a greater extent than @entity12833 or @entity1169 in a study designed specifically to determine the effect of treatment on the quality of life of @entity1 with mild or moderate essential @entity101 . The earlier demonstrated efficacy of @entity3371 , used with a diuretic and often also with a beta-adrenoceptor blocking drug, in the treatment of severe @entity101 refractory to conventional 'triple therapy' has been confirmed in more recent trials which illustrate the generally marked antihypertensive effect of @entity3371 -containing regimens in such @entity1 . Results of initial trials in @entity1 with @entity2631 are promising, with control of @entity101 and stabilization of renal function in these @entity1 when treated at an early stage of the disease. Several comparative and long term trials of @entity3371 in @entity1 with chronic @entity712 refractory to treatment with a diuretic/digitalis regimen clearly demonstrate that initial haemodynamic improvement is maintained and correlates with clinical benefit. A tendency for overall clinical response to @entity3371 to be better than the response to @entity3159 , @entity2514 , @entity10129 or @entity4688 has been reported. Results of a multicentre comparison with digoxin and placebo indicate that @entity3371 is a suitable alternative to digoxin in @entity1 with mild to moderate @entity712 who are receiving maintenance diuretic therapy. The tolerability of @entity3371 has now been studied in many thousands of @entity1 involved in formalized trials and the early impression of poor tolerability can no longer be justified. The use of generally lower dosages of @entity3371 in @entity1 with normal or slightly @entity8 has resulted in a generally low incidence of @entity1910 (0.5 to 4%), @entity2342 (0.1 to 3%), @entity644 (0.5%), @entity1398 (0.3% during first 3 months) and symptomatic @entity551 (0.1 to 3%). Cough is an infrequent but troublesome effect resulting from @entity1289 inhibition.(ABSTRACT TRUNCATED AT 400 WORDS)
